香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 Kangji Medical Holdings Limited 康基医疗控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9997） 截至2023年6月30日止六個月的 中期業績公告 康基医疗控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）欣然宣佈，本集團截至2023年6月30日止六個月（「報告期」）的未經審 核綜合中期業績連同2022年同期的比較數據如下： | --- | --- | --- | --- | |----------------------------------------------|-------------------------------------|-------------------------------------|-----------| | | | | | | 財務摘要 | 截至 6 月 30 | 日止六個月 ...

Financial Performance - Kangji Medical achieved a revenue of RMB 786.4 million in 2022, representing a year-on-year growth of approximately 13.9%[6] - The net profit attributable to the company's shareholders was RMB 498.7 million, reflecting a year-on-year increase of about 21.0%[6] - The company achieved revenue of RMB 786.4 million for the year ended December 31, 2022, representing a 13.9% increase compared to 2021[11] - The net profit attributable to the company's shareholders increased by 4.8% to RMB 478.7 million in 2022, up from RMB 456.8 million in 2021[11] - The adjusted net profit (excluding fair value gains on equity investments, foreign exchange differences, and short-term financial product gains/losses) rose by 21.0% to RMB 498.7 million in 2022 from RMB 412.1 million in 2021[14] - Export sales reached RMB 71.3 million, a significant increase of 46.9% year-on-year, with a constant currency growth of approximately 41.1%[13] - Disposable products revenue reached RMB 689.1 million for the year ended December 31, 2022, a 13.1% increase from RMB 609.3 million in 2021, primarily driven by growth in sales of disposable puncture cannulas, polymer ligating clips, and disposable electrocautery forceps[21] - Revenue from disposable puncture cannulas was RMB 364.9 million, up 9.2% from RMB 334.1 million in 2021, accounting for approximately 46.4% of total revenue[21] - Revenue from polymer ligating clips increased by 7.9% to RMB 192.5 million, with sales growth affected by regional procurement uncertainties[21] - Revenue from repeatable products was RMB 97.2 million, a 20.2% increase from RMB 80.9 million in 2021, mainly due to increased sales of the 4K endoscope imaging system launched in the first half of 2021[22] - Overseas market revenue was approximately RMB 71.3 million, a 46.9% increase from RMB 48.5 million in 2021, with export sales growing by 41.1% in USD terms[23] - Gross profit increased by 12.8% to RMB 635.2 million, with a gross margin of 80.8%, down from 81.6% in 2021 due to changes in product mix[27] Strategic Initiatives - Kangji Medical plans to invest more in the development of innovative and equipment-related products, with a focus on establishing a new R&D center to enhance advanced product design capabilities[7] - The company aims to expand its international sales and marketing teams to achieve rapid growth in overseas sales[7] - Kangji Medical is actively seeking strategic investment and collaboration opportunities to enhance its scale and influence in the market[7] - The company plans to expand its international sales and marketing team to achieve sustained rapid growth in overseas sales[18] - The company completed the acquisition of a 35% stake in Weijing Medical, which focuses on laparoscopic surgical robot products, contributing a loss of approximately RMB 27.0 million for the year[17] - The company plans to utilize net proceeds from its global offering for strategic investments and capital asset acquisitions, although no specific plans were disclosed[46] - The company has engaged in long-term collaborative research and development with top 20 hospitals in China to enhance clinical solutions[171] - The company is exploring potential mergers and acquisitions to enhance its market position[55] Research and Development - Kangji Medical emphasizes a clinical-oriented R&D approach to drive innovation and product development[7] - The company aims to enhance its clinical-oriented R&D approach and invest more in innovative products to provide comprehensive solutions in minimally invasive surgery[18] - In 2022, the company registered 11 new products in mainland China and 13 new product registrations in overseas markets, primarily in South America[15] - Investment in R&D increased by 20% compared to the previous year, emphasizing innovation[52] - The company implemented a new production process execution system (MES) in its highly automated workshops, enhancing product management precision to each machine and allowing real-time monitoring of production status[189] - The company upgraded its injection molding equipment to electric servo machines, improving manufacturing precision by approximately 57%[189] - The company initiated the MDR certification project to comply with the new EU regulations, collaborating with third-party consulting firms to optimize its quality management system[198] Market Expansion - The company expanded its export market presence from 45 countries and regions to 47, with over 100 customers as of December 31, 2022[13] - The company continues to focus on various surgical specialties, including gynecology, general surgery, urology, and thoracic surgery, providing comprehensive solutions[6] - The company is currently providing products and services to nearly 50 countries and regions, including over 3,500 hospitals in China, with more than 1,000 being top-tier hospitals[171] - Market expansion plans include entering three new international markets by Q4 2023[56] Corporate Governance - The company has a strong management team with extensive experience in finance, accounting, and medical technology[61] - The company has established four board committees, including the Audit Committee, Nomination Committee, Remuneration Committee, and ESG Committee, to oversee specific areas of governance[124] - The company emphasizes the importance of corporate governance as a shared responsibility among directors, including compliance with legal and regulatory requirements[138] - The board has proposed a final dividend of RMB 0.1845 per share for the year ended December 31, 2022, subject to shareholder approval at the annual general meeting[116] - The company has adopted a shareholder communication policy to ensure equal and timely access to information for shareholders[156] Environmental, Social, and Governance (ESG) - The company has set detailed environmental goals in line with the national strategy of "carbon peak by 2030 and carbon neutrality by 2060" during the reporting period[169] - The company has developed a comprehensive ESG governance structure, which includes the board, an ESG committee, and an ESG working group[174] - The company emphasizes communication with stakeholders to understand their expectations and concerns, facilitating better management decisions[177] - The company has established a risk management system that incorporates ESG risks into its overall risk management framework[173] - 康基医疗在2022年维持了CE认证的有效性，并通过了ISO13485与ISO9001质量管理体系的审核[185] - 公司建立了产品全生命周期质量控制体系，确保从研发设计到售后保障各环节的质量管理[185] - 康基医疗识别并总结出22项ESG重要性议题，其中4项为高度重要性议题，17项为中度重要性议题[180] Employee and Compensation - Employee headcount rose to 885 as of December 31, 2022, from 725 in the previous year, marking a 22% increase[47] - Total employee compensation expenses for the year amounted to RMB 127.8 million, up from RMB 93.3 million in 2021, reflecting a 37% increase[47] - The company has adopted a pre-IPO share option plan and a restricted share unit plan to attract and retain top talent in key positions[95] - The total number of restricted shares under the Restricted Share Unit Plan was increased from 26,810,000 shares to 46,810,000 shares as approved by shareholders on May 25, 2022[108] Risk Management - The company has established a risk management and internal control system, which is regularly reviewed by the board[140] - Financial risks include credit risk, currency risk, interest rate risk, and liquidity risk, with management policies outlined in the financial statements[68] - The company does not have a specific dividend policy or predetermined dividend payout ratio, with future dividend payments to be decided at the board's discretion based on profitability, cash flow, financial condition, and other relevant factors[149] Shareholder Relations - The company emphasizes effective communication with shareholders to strengthen investor relations and ensure timely disclosure of information[155] - The company provides contact information for shareholders to raise inquiries directly to the board[159] - The company guarantees the report's content is free from false statements, misleading representations, or significant omissions[165]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部 或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Kangji Medical Holdings Limited 康基医疗控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9997） 截至2022年12月31日止年度的 年度業績公告 康基医疗控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）欣然宣佈，本集團截至2022年12月31日止年度（「報告期」）的經審核 綜合年度業績連同截至2021年12月31日止年度的比較數據如下。 | --- | --- | --- | --- | |---------------------------------------------------|---------------------------------------|----------------------------------------|-------------------| | | | | | | ...

Financial Performance - The company reported revenue of RMB 332.3 million for the six months ended June 30, 2022, representing a 4.5% increase compared to RMB 318.1 million in the same period of 2021[7]. - Gross profit for the same period was RMB 265.7 million, slightly up from RMB 261.2 million in 2021[7]. - Profit attributable to owners of the parent decreased by 20.9% to RMB 157.7 million from RMB 199.4 million in 2021, primarily due to increased administrative and R&D expenses[8]. - Adjusted net profit for the period increased by 7.0% to RMB 215.3 million from RMB 201.2 million in 2021[8]. - The overall sales recorded slight positive growth compared to the same period in 2021 despite the challenges posed by COVID-19[9]. - Revenue for the six months ended June 30, 2022, was RMB 332,321 thousand, an increase from RMB 318,124 thousand in the same period of 2021, representing a growth of 4.0%[66]. - Gross profit for the same period was RMB 265,712 thousand, compared to RMB 261,227 thousand in 2021, reflecting a slight increase[66]. - The company reported a profit of RMB 153,497 thousand for the six months ended June 30, 2022, down from RMB 199,358 thousand in 2021, indicating a decrease of 23.1%[66]. Sales and Market Expansion - Export sales reached RMB 30.5 million, a significant increase of 45.9% compared to the same period last year, with approximately 80 customers across 42 countries and regions[9]. - The company has prioritized expanding and increasing export sales, with a focus on enhancing international sales and marketing teams[9]. - The company experienced a rebound in surgical volume and product demand in June 2022, following a decline due to COVID-19 restrictions earlier in the year[9]. - The company has increased overseas product registrations, particularly in South America, to support its export growth strategy[9]. - Revenue from disposable products reached RMB 293.0 million, a 3.9% increase from RMB 282.0 million in the same period of 2021[19]. - Revenue from reusable products increased by 8.8% to RMB 39.3 million, compared to RMB 36.1 million in the same period of 2021[20]. - Overseas market revenue grew by 45.9% to RMB 30.5 million, accounting for 9.2% of total revenue, up from 6.6% in 2021[21]. Expenses and Costs - Total sales cost increased by 17.0% to RMB 66.6 million, compared to RMB 56.9 million in the same period of 2021[23]. - Administrative expenses for the six months ended June 30, 2022, were RMB 336 million, an increase of 30.7% compared to RMB 257 million for the same period in 2021[29]. - Research and development expenses for the six months ended June 30, 2022, were RMB 263 million, a 63.5% increase from RMB 161 million for the same period in 2021, primarily due to contributions from the acquisition of Weijing Medical amounting to RMB 73 million[30]. - Sales and distribution expenses rose by 13.7% to RMB 23.9 million, compared to RMB 21.0 million in the same period of 2021[28]. - The cost of sold inventory for the first half of 2022 was RMB 66,609,000, compared to RMB 56,897,000 in 2021, indicating an increase of 17.1%[86]. Investments and Acquisitions - The company acquired a 35% stake in Hangzhou Weijing Medical Robotics Co., which will serve as a future platform for surgical robot products[12]. - The company acquired a 32.75% stake in Weijing Medical for RMB 340 million and an additional 2.25% stake for RMB 22.87 million, resulting in a total investment of RMB 362.87 million[42]. - Following the investment, Weijing Medical became an indirect non-wholly owned subsidiary, with a 35% equity interest held by the company[42]. - The company has no plans for any other significant investments or acquisitions as of the report date[43]. Cash Flow and Financial Position - Cash and cash equivalents as of June 30, 2022, were RMB 30,565 million, up from RMB 29,537 million as of December 31, 2021[36]. - The net current assets as of June 30, 2022, were RMB 30,099 million, a decrease of RMB 419 million from RMB 30,518 million as of December 31, 2021[37]. - The company reported a net loss from investments in financial assets measured at fair value of RMB 23,532,000 in the first half of 2022, compared to a gain of RMB (6,942,000) in the same period of 2021[74]. - The company’s total cash and cash equivalents decreased by RMB 242,341,000 in the first half of 2022, compared to a decrease of RMB 592,310,000 in the same period of 2021[75]. Employee and Management - As of June 30, 2022, the total employee count was 846, an increase from 694 employees as of June 30, 2021, representing a growth of approximately 21.9%[44]. - Total employee compensation expenses for the six months ended June 30, 2022, amounted to RMB 62.3 million, compared to RMB 36.5 million for the same period in 2021, reflecting an increase of approximately 70.8%[44]. - The employee distribution by function shows that 61.7% are in production, 15.4% in R&D, and 8.0% in sales and marketing[45]. - Total remuneration for key management personnel was RMB 9,441,000 for the six months ended June 30, 2022, compared to RMB 8,135,000 for the same period in 2021[108]. Compliance and Governance - The company emphasizes compliance with the Corporate Governance Code in its operations[115]. - The company has a defined standard code for securities trading by its directors[115]. - The company is committed to maintaining transparency and accountability in its financial disclosures[115].

目錄 2 公司資料 1 目錄 康基医疗控股有限公司 | 2021中期報告 目錄 3 財務摘要 4 管理層討論與分析 14 企業管治及其他資料 20 中期簡明綜合損益及其他全面收益表 22 中期簡明綜合財務狀況表 24 中期簡明綜合權益變動表 25 中期簡明綜合現金流量表 27 中期簡明綜合財務資料附註 41 釋義 康基医疗控股有限公司 | 2021中期報告 公司資料 董事會 執行董事 鍾鳴先生 （董事長） 申屠銀光女士 Frances Fang CHOVANEC（陳芳）女士 非執行董事 蔡俐女士 陳剛先生 獨立非執行董事 姜峰先生 郭建先生 陳衛波先生 審核委員會 陳衛波先生 （主席） 姜峰先生 蔡俐女士 薪酬委員會 陳衛波先生 （主席） 申屠銀光女士 郭建先生 提名委員會 鍾鳴先生 （主席） 姜峰先生 郭建先生 聯席公司秘書 尹自鑫先生 梁瑞冰女士 （ACG 、ACS） 授權代表 鍾鳴先生 尹自鑫先生 核數師 安永會計師事務所 執業會計師 註冊公眾利益實體核數師 香港 鰂魚涌 英皇道979 號 太古坊一座27 樓 合規顧問 新百利融資有限公司 香港 皇后大道中29 號 華人行20 樓 註冊辦事處 Maple ...